close

Join our Mailing List

Receive the latest news, event invites, funding opportunities and more from the Ontario Institute for Cancer Research.

Search Results for: compass – Page 3

OICR_FACIT
FACIT's Prospects Oncology Fund invests in Ontario-developed medical device and novel therapeutic platform technologies
Niche early-stage investment program seeds Ontario’s developing pipeline of oncology assets  TORONTO, ON (September 26, 2019) – Three promising Ontario-based oncology innovations are recipients of seed capital through the latest round of FACIT’s Prospects Oncology Fund. Medical device...
rob
Study reveals mechanism driving spread of advanced pancreatic cancer
Rob Denroche, bioinformatician and Project Leader of PanCuRx. Large-scale pancreatic cancer study distinguishes primary from metastatic tumours, uncovering new genomic biomarkers that could help guide treatment selection Over the next decade, pancreatic ductal adenocarcinoma (PDAC) – the most common...
facit-logo
FACIT makes follow-on investment in AI-based genomics company, DNAstack
Capital leverages Ontario’s strengths in genomics and informatics, deepens FACIT’s tech portfolio (more…)
nicholas-khuu
Meet the researchers - Nicholas Khuu
What does a ball of elastic bands have to do with cancer research? Watch Nick Khuu explain. Nick is a Quality Assurance Coordinator in OICR’s genomics lab working on sequencing for OICR’s COMPASS clinical trial. He uses an #elasticbandball to explain #sequencingcoverage and how this sequencing...
oicr-abstact-bkg-2
Canadian pancreatic cancer research team provides personalized medicine, new hope to patients
VANCOUVER – Canadian pancreatic cancer researchers are joining forces under a Terry Fox initiative bringing new hope for patients with this deadly disease. “For many years it’s been hopeless from a patient perspective, and we are hoping to help shift this,” says Dr. Daniel Renouf (BC Cancer, University...
GA-GLOBE_NEWSv2
Global Alliance for Genomics and Health launches 2018 Strategic Roadmap
The Global Alliance for Genomics and Health (GA4GH) has laid out its plans for the next five years as it continues to align its activities with meeting the key needs of the genomics data community. The Strategic Roadmap encompasses the standards and frameworks that will be developed by GA4GH and will...
holiday-2
Happy holidays from OICR
The holidays are filled with traditions old and new, whether it’s a turkey dinner, a movie with friends, a long flight home or an annual trip south to get away from the cold. At OICR we have staff and collaborators from all over the world, and it is always amazing to hear about everyone’s unique plans...
pancreas-image-2
OICR-led study finds four unique genomic signatures in pancreas cancer, uncovers potential of immunotherapies
Pancreas cancer is one of the most aggressive and deadly forms of the disease. According to the Canadian Cancer Society, only 8 percent of pancreas cancer patients survive more than five years after diagnosis. OICR’s PanCuRx Translational Research Initiative has recently published the results of an international...

FACIT’s Prospects Oncology Fund invests in Ontario-developed medical device and novel therapeutic platform technologies

Niche early-stage investment program seeds Ontario’s developing pipeline of oncology assets  TORONTO, ON (September 26, 2019) – Three promising Ontario-based oncology innovations are recipients of seed capital through the latest round of FACIT’s Prospects Oncology Fund. Medical device start-up Xpan Inc., Dr. Igor Stagljar of the University of Toronto, and the Drug Discovery Program at the Ontario Institute for Cancer Research (OICR) were selected to receive seed funding among a

Study reveals mechanism driving spread of advanced pancreatic cancer

Large-scale pancreatic cancer study distinguishes primary from metastatic tumours, uncovering new genomic biomarkers that could help guide treatment selection Over the next decade, pancreatic ductal adenocarcinoma (PDAC) – the most common type of pancreatic cancer – is projected to become the second leading cause of all cancer mortality. A better understanding of how PDAC changes when it metastasizes – or spreads from the pancreas to other organs – may help

Meet the researchers – Nicholas Khuu

What does a ball of elastic bands have to do with cancer research? Watch Nick Khuu explain. Nick is a Quality Assurance Coordinator in OICR’s genomics lab working on sequencing for OICR’s COMPASS clinical trial. He uses an #elasticbandball to explain #sequencingcoverage and how this sequencing technique can provide extra information to health care providers when treating patients with pancreatic cancer.

Canadian pancreatic cancer research team provides personalized medicine, new hope to patients

VANCOUVER – Canadian pancreatic cancer researchers are joining forces under a Terry Fox initiative bringing new hope for patients with this deadly disease. “For many years it’s been hopeless from a patient perspective, and we are hoping to help shift this,” says Dr. Daniel Renouf (BC Cancer, University of British Columbia) who, along with Dr. David Schaeffer (UBC, Vancouver General Hospital), is leading a $5-million pan-Canadian, precision medicine initiative recently funded

Global Alliance for Genomics and Health launches 2018 Strategic Roadmap

The Global Alliance for Genomics and Health (GA4GH) has laid out its plans for the next five years as it continues to align its activities with meeting the key needs of the genomics data community. The Strategic Roadmap encompasses the standards and frameworks that will be developed by GA4GH and will be updated with new deliverables annually. OICR is a GA4GH Host Institution.

Happy holidays from OICR

The holidays are filled with traditions old and new, whether it’s a turkey dinner, a movie with friends, a long flight home or an annual trip south to get away from the cold. At OICR we have staff and collaborators from all over the world, and it is always amazing to hear about everyone’s unique plans as they gear up for the end of the year.

OICR-led study finds four unique genomic signatures in pancreas cancer, uncovers potential of immunotherapies

Pancreas cancer is one of the most aggressive and deadly forms of the disease. According to the Canadian Cancer Society, only 8 percent of pancreas cancer patients survive more than five years after diagnosis. OICR’s PanCuRx Translational Research Initiative has recently published the results of an international collaboration that increases understanding of this complex disease and how to treat it based on a patient’s unique profile.